Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about IVVD, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Adintrevimab (ADG20) | COVID-19 | Phase 2/3 · NCT04859517 | Terminated |
| mRNA COVID-19 Vaccine | COVID-19 | Phase 3 · NCT07655180 | Completed |
| VYD222 | COVID-19 | Phase 3 · NCT06039449 | Completed |
| VYD2311 | COVID-19 | Phase 3 · NCT07655180 | Completed |
| VYD2311-MD | COVID-19 | Phase 3 · NCT07298434 | Active not recruiting |
| VYD2311-SD | COVID-19 | Phase 3 · NCT07298434 | Active not recruiting |
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
IVVD holds $126.4M in cash and short-term investments (as of Sep 30, 2026) and burns about $37.6M/quarter from operations, an estimated runway of 10.1 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 90 · High
Based on current operating plans and excluding future external financing, the Company will not have sufficient cash and cash equivalents to fund its operating expenses and capital requirements beyond one year from the issuance of these condensed consolidated financial statements, and therefore, the Company has…10-Q, Nov 2026
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when IVVD files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Janus Henderson Group Ltd. | Institution (13F) | 35,996,902 | 12.21% | 2026-09-30 |
| BVF PARTNERS L P/IL | Institution (13G, 5%+) | 29,571,826 | 10.03% | 2026-06-30 |
| BVF Inc. | Institution (13F) | 28,165,000 | 9.56% | 2026-09-30 |
| Maverick Capital, Ltd. | Institution (13G, 5%+) | 24,442,160 | 8.29% | 2026-09-30 |
| RA Capital Management, L.P. | Institution (13G, 5%+) | 21,342,442 | 7.24% | 2026-03-31 |
| Adimab, LLC 10% owner |
Insider | 20,262,170 | 6.87% | 2025-12-23 |
| BlackRock, Inc. | Institution (13G, 5%+) | 16,124,696 | 5.47% | 2026-06-30 |
| Perceptive Advisors Llc | Institution (13F) | 13,762,637 | 4.67% | 2026-09-30 |
| Ajay Royan Director · +158,219 options |
Insider | 11,241,580 | 3.81% | 2025-03-22 |
| Vanguard Capital Management LLC | Institution (13F) | 10,979,581 | 3.72% | 2026-09-30 |
| M28 Capital Management LP | Institution (13F) | 9,248,250 | 3.14% | 2026-09-30 |
| Soleus Capital Management, L.P. | Institution (13F) | 7,524,958 | 2.55% | 2026-09-30 |
Share count 294,758,746 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.
| Trade date | Insider | Transaction | Shares | Price | Owned after |
|---|---|---|---|---|---|
| 2026-08-31 filed 2026-09-02 |
Sheffield Ian |
Option award (A) | 100,000 | – | – |
| 2026-08-30 filed 2026-09-01 |
Elia Marc |
Option award (A) | 10,700,000 | – | – |
| 2026-08-18 filed 2026-08-18 |
Lee Timothy Edward |
Sale (S) | 18,425 | $0.84 | 178,937 |
| 2026-08-18 filed 2026-08-18 |
Green Julie |
Sale (S) | 18,425 | $0.84 | 168,937 |
| 2026-08-18 filed 2026-08-18 |
Andersen Jill |
Sale (S) | 30,706 | $0.84 | 283,774 |
Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for IVVD and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →